Sarcoma Study of MORAb-004 Utilization: Research and Clinical Evaluation

Summary

This study is being done to see if MORAb-004 increases the effectiveness of the chemotherapies gemcitabine and docetaxel in people with metastatic Soft Tissue Sarcoma.

Timeline

Start

2012-08-07

Primary completion

2015-08-11

Completion

2016-08-02

Outcome

Missed primary endpoint

registry p = 0.6562; Hazard Ratio (HR) 1.08 (95% CI 0.77 to 1.50); Log Rank NCT01574716 ↗

Publications

• Jones RL, Chawla SP, Attia S, Schoffski P, Gelderblom H, Chmielowski B, Le Cesne A, Van Tine BA, Trent JC, Patel S, Wagner AJ, Chugh R, Heyburn JW, Weil SC, Wang W, Viele K, Maki RG. A phase 1 and randomized controlled phase 2 trial of the safety and efficacy of the combination of gemcitabine and docetaxel with ontuxizumab (MORAb-004) in metastatic soft-tissue sarcomas. Cancer. 2019 Jul 15;125(14):2445-2454. doi: 10.1002/cncr.32084. Epub 2019 Apr 29.

Drugs

Indications